BioSpace News Archive

GenSight Biologics announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society in Honolulu, Hawaii.

CytoMed Therapeutics Limited announced that it has entered into a Research Collaboration Agreement with Sengkang General Hospital Pte Ltd, a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, umbilical cord-derived mesenchymal stem cells to treat cartilage injury.

SOLASCURE Ltd has announced the publication of its CLEANVLU Phase IIa clinical trial report in the International Wound Journal, a leading wound care journal.1 SolasCure’s first investigational product, Aurase Wound Gel, is a hydrogel releasing tarumase, a recombinant enzyme derived from medical maggots, which aims to promote wound healing through debridement and wound bed preparation.

Akero Therapeutics, Inc. released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, fibrosis stage 2 or 3.

Zura Bio Limited a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced that members of its senior management team will participate in three conferences in March.

Berlin Cures, a clinical-stage biotechnology company, has reached a significant milestone in its Europe-wide clinical trial for Long COVID, effectively enrolling over 50% of the targeted 114 patients and expanding the study’s inclusion criteria.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted seven newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on March 1, 2024 as inducements material to each employee entering into employment with KalVista.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) today announced that the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold placed on the registrational IOV-LUN-202 trial investigating LN-145 TIL cell therapy in non-small cell lung cancer (NSCLC).

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced the appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer to succeed Dario Paggiarino, M.D. who has served as EyePoint’s Chief Medical Officer since 2016.